MIR MedMira Inc.
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.…
Industry Peers
BiotechnologyKey Statistics
About MedMira (CVE: MIR)
›
MedMira (CVE: MIR) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0600 CAD on 18 November 2026, down 45.0% over 52 weeks. Its 52-week range is 0.0300 CAD to 0.1000 CAD: the price is 40.0% below the high and 100.0% above the low.
Its market capitalisation is 38.60M CAD.
MedMira reports return on equity of 20.1% and revenue up 308.0% year over year.
Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 27 November 2026.